Backing US biotech from pre-seed to Series A.
Investing in US teams and companies whose edge is scientific.
We invest in early-stage companies with a differentiated scientific capability and a team committed to developing it. Our focus includes academic spinouts and companies built around proprietary technology, biological insight or data.
Five things we look for in early-stage investments.
A capability that matters
A clear answer to “why now”: causal target biology, design-to-spec or a delivery unlock, with high potential for impact.
Research at the frontier
Teams whose work is published in leading peer-reviewed journals and who are recognized in their fields.
Protected IP
Differentiated intellectual property developed by, or with, the scientific founders.
A testable path to evidence
A credible go/no-go the next round can fund, not just a hypothesis.
A team that can build
Founders who can turn the science into commercializable products and solutions.
Building a biotech company?
Get in touch with our venture team.
